Economic evaluation of a tablet-based vaccination against hay fever in Denmark;Økonomisk evaluering af tabletbaseret vaccine mod høfeber i Danmark

Ugeskrift for Laeger

Volumn 170, Issue 3, 2008, Pages 138-142

  Poulsen, Peter Bo ^a,b   Pedersen, Kjeld Møller ^a   Christensen, Jens ^a   Vestenbæk, Ulrik ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b MUUSMANN Research and Consulting   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIALLERGIC AGENT; VACCINE;

ADULT; ARTICLE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DESENSITIZATION; DRUG COST; ECONOMICS; HAY FEVER; HUMAN; IMMUNOLOGY; METHODOLOGY; POACEAE; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; SUBLINGUAL DRUG ADMINISTRATION; TABLET;

ADMINISTRATION, SUBLINGUAL; ADULT; ALLERGENS; ANTI-ALLERGIC AGENTS; COST-BENEFIT ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; DRUG COSTS; HUMANS; POACEAE; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RHINITIS, ALLERGIC, SEASONAL; TABLETS; VACCINES;

EID: 38749149639     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Dahl R, Andersen PS, Chivato T et al. National prevalence of respiratory allergic disorders. Respir Med 2004;98:398-403.
2. Bauchau V Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64.
3. Grossman J. One airway, one disease. Chest 1997;111:6-11.
4. Mossing R, Nielsen GD. De samfundsøkonomiske omkostninger ved astma i Danmark i 2000. Ugeskr Læger 2003;165:2646-9.
5. Institut for Rational Farmakoterapi (IRF). Allergisk rhinitis. Månedsbladet Rational Farmakoterapi nr.3, marts 2003.
6. Walker SM, Varney VA. Gaga M et al. Grass pollen allergen specific immunotherapy. Allergy 1995;50:405-13.
7. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen allergen specific immunotherapy. N Engl J Med 1999;34:468-75.
8. Bousquet J, Lockey R, Mailing HJ et al. Alergen specific immunotherapy: Therapeutic Vaccines for Alergie Diseases Allergy, World Health Organization and American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:401-5.
9. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass pollen allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006;61:185-90.
10. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;11B:434-40.
11. Pedersen K, Wttrup-Jensen K, Brooks Ret al. Vaardisastning af sundhed. Teorien om kvalltetsjusterede leveár og en dansk anvendelse. Odense: Syddansk Universitetsforlag, 2003.
12. European Federation of Allergy and Airway Diseases Patients Association (EFA). Results of the patient voice allergy survey. Impact of allergic rhinitis in Europe. Summary Report (2005). www.efanet.org/jan 2007.
13. Lamb CE, Ratner PH, Johnson CE et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with selected medical conditions in the United States from an employer perspective. Curr Med Res Opin 2006;22:1203-10.
14. Alban A, Keiding H, Søgaard J. Retningslinier for samfundsøkonomiske analyser af Iægemidler. København: Sundhedsministeriets Medicinudvalg, marts 1998.
15. National Institute of Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE, 2004.
16. Mosbech H, Østerballe O. Does the effect of allergen specific immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988;43:523-9.
17. Di-Rienzo V Marcucci F, Puccinelli Pet al. Long-lasting effect of sublingual allergen specific immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206-10.
18. Möller C, Dreborg S, Ferdousi HA et al. Pollen allergen specific immunotherapy reduces the development of asthma in children with seasonal rhinitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-6.
19. Haamann P, Larsen M, Hauschildt Juhl H et al. Fotodynamisk behandling af karnydannelse bag øjets nethinde-en medicinsk teknologivurdering. Medicinsk Teknologivurdering - puljeprojekter 2002;2(3). København: Sundhedsstyrelsen, Center for Evaluring og Medicinsk Teknologivurdering, 2002.
20. Devlin N, Parkin D. Does NICE have a cost effectiveness threshold, and what other factors influence its decisions? A binary choice model. Health Economics 2004;13:437-52.
21. Creticos PS, van Metre TE Jr, Mardiney MR et al. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984;73:94-104.